Differential Interactions of Nateglinide and Repaglinide on the Human β-Cell Sulphonylurea Receptor 1
- Ann Maria K. Hansen1,
- Inge T. Christensen1,
- John Bondo Hansen1,
- Richard D. Carr1,
- Frances M. Ashcroft2 and
- Philip Wahl1
- 1Discovery, Novo Nordisk A/S, Bagsvaerd, Denmark
- 2University Laboratory of Physiology, Oxford University, Oxford, U.K.
Repaglinide and nateglinide represent a new class of insulin secretagogues, structurally unrelated to sulphonylureas, that were developed for the treatment of type 2 diabetes. The inhibitory effect of these drugs was investigated on recombinant wild-type and mutant Kir6.2/SUR1 channels expressed in HEK293 cells. Nateglinide and repaglinide dose-dependently inhibited whole-cell Kir6.2/SUR1 currents with half-maximal inhibitory concentration (IC50) values of 800 and 21 nmol/l, respectively. Mutation of serine 1237 in SUR1 to tyrosine (S1237Y) abolished tolbutamide and nateglinide block, suggesting that these drugs share a common point of interaction on the SUR1 subunit of the ATP-sensitive K+ channel. In contrast, repaglinide inhibition was unaffected by the S1237Y mutation (IC50 = 23 nmol/l). Radioligand binding studies revealed a single high-affinity binding site for [3H]repaglinide on membranes prepared from HEK293 cells expressing wild-type (equilibrium dissociation constant [KD] = 0.40 nmol/l) or mutant (KD = 0.31 nmol/l) Kir6.2/SUR1 channels. Nateglinide and tolbutamide displaced [3H]repaglinide binding to wild-type channels with IC50 values of 0.7 and 26 μmol/l, respectively, but produced <10% displacement of [3H]repaglinide bound to mutant channels. This is consistent with the idea that binding of nateglinide and tolbutamide, but not repaglinide, is abolished by the SUR1[S1237Y] mutation and that the binding site for repaglinide is not identical to that of nateglinde/tolbutamide. These results are discussed in terms of a conformational analysis of the drug molecules.
Address correspondence and reprint requests to Dr. Philip Wahl, Department of Islet Discovery Research, Discovery, Novo Allé, Novo Nordisk A/S, DK-2880 Bagsvaerd, Denmark. E-mail:.
Received for publication 21 December 2001 and accepted in revised form 7 June 2002.
F.M.A. is a paid consultant for Novo Nordisk.
GFP, green fluorescent protein; IC50, half-maximal inhibitory concentration; KATP, ATP-sensitive K+; KD, equilibrium dissociation constant; SUR, sulphonylurea receptor; TM, transmembrane.